Euractiv.com

Plus mini-omnibus, green opt-outs, and Ukraine defence corruption

A hard-won compromise gives the EU something to show at the COP30 climate jamboree but sees domestic ambition slashed

The EU-Singapore digital trade agreement is not in compliant with EU rules and fundamental rights and should be assessed by the EU Court of Justice, left-wing MEPs argue

In today's edition: Biocontrol, EU-US tariffs, NGTs

In today's edition: Price transparency, CMA, contraception and tobacco

In today's edition: 2040 deal, EU clean transport plan, 1.5 no longer alive

In today’s edition: Norway could unlock the EU’s frozen-assets loan to Ukraine by tapping its sovereign wealth fund, Parliament threatens to torpedo the Commission’s €2 trillion budget proposal, and ex-Justice Commissioner Didier Reynders faces money laundering charges

Lawmakers call for greater drug price transparency as EU debates new pharma laws

Opt for ambitious overhaul or suffer from higher bills, warn government advisors

Migration continues to be at the forefront of public debate

Parliament and Council near deal to expand Horizon Europe to dual-use projects

Billions of euros in EU money are being targeted at ramping up the bloc's AI capacity but it’s hard to say where this big investment will land Europe in the global AI race

Residents now fear what may happen once the police leave

The compromise agreement, which adds flexibilities sought by holdout countries, came a day before the COP30 summit in Brazil

Air traffic was also halted as a precaution at the second-largest airport Charleroi

If Europe is to fight its corner in an increasingly predatory world of growing technical complexity, a fresh intake of competent young staff is imperative

Prosecutors say Vučić overstepped his powers after branding them a ‘corrupt gang’ on TV

A typical 'chicken-and-egg problem', says German lawmaker Peter Liese

Green MP Nicolas Thierry says the plan sends a powerful message that tobacco will no longer be part of future generations’ lives

The report calls for indefinite approvals for low-risk biopesticides, though some warn this could raise safety concerns